Page 1

Contact : Investors : Traci McCarty BioMarin Pharmaceutical Inc. ( 415 ) 455-7558 Exhibit 99.1 BIOMARIN Media : Debra Charlesworth BioMarin Pharmaceutical Inc. ( 415 ) 455-7451 • BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates Strong Commercial Launch of VOXZOGO ™ for the Treatment of Children with Achondroplasia Ages 2 and Older Underway across Europe ; U.S. Review Proceeding , Target Action Date Tracking to November 20 , 2021 European Opinion on the Marketing Authorization Application ( MAA ) for Valoctocogene Roxaparvovec , for the Treatment of Severe Hemophilia A , Expected First Half 2022 ; U.S. Resubmission of Biologics License Application ( BLA ) in U.S. on Track for Second Quarter 2022 . Improving Full - year 2021 Total Revenue and Bottom - line Financial Guidance Multiple Early - stage Programs to be Shared at Upcoming BioMarin R & D Day on November 30 , 2021 Financial Highlights ( in millions of U.S. dollars , except per share data , unaudited ) Three Months Ended September 30 , 2021 2020 % Change Nine Months Ended September 30 , 2021 2020 % Change Total Revenues $ 408.7 $ 476.8 Net Product Revenues Marketed by BioMarin ( 1 ) $ 369.5 $ 419.8 ( 14 ) % $ ( 12 ) % $ 1,396.5 $ 1,245.8 $ 1,408.3 1,239.9 ( 1 ) % ― % Vimizim Net Product Revenues Naglazyme Net Product Revenues Kuvan Net Product Revenues Palynziq Net Product Revenues Brineura Net Product Revenues Voxzogo Net Product Revenues Aldurazyme Net Product Revenues GAAP Net Income ( Loss ) EA EA EA EA EA EA $ 136.9 $ 147.9 ( 7 ) % $ 466.8 $ 401.8 16 % $ 71.2 $ 76.3 ( 7 ) % $ 297.3 $ 271.6 9 % $ 67.7 $ 124.1 ( 45 ) % $ 217.3 $ 60.7 $ 46.1 32 % $ 173.7 $ 32.9 $ 25.4 30 % $ 90.6 $ 0.1 $ n / a $ 0.1 EA EA EA EA $ 368.7 ( 41 ) % $ 121.4 43 % $ 75.2 20 % $ n / a GAAP Net Income ( Loss ) per Share - Basic GAAP Net Income ( Loss ) per Share - Diluted Non - GAAP Income ( 2 ) SASASAAAAA $ 24.4 $ 40.9 ( 40 ) % $ 102.5 $ 128.9 ( 20 ) % $ ( 36.5 ) $ 784.8 $ ( 6.2 ) $ 837.0 $ ( 0.20 ) $ 4.33 $ ( 0.03 ) $ 4.63 $ $ ( 0.20 ) $ 33.5 4.01 $ ( 0.03 ) $ 4.39 $ 98.7 $ 235.7 $ 272.6 Cash , cash equivalents and investments September 30 , 2021 December 31 , 2020 $ 1,546.1 $ 1,350.9 ( 1 ) Net Product Revenues Marketed by BioMarin is the sum of revenues from Vimizim , Naglazyme , Kuvan , Palynziq , Brineura and Voxzogo ( formerly known as vosoritide ) for the three and nine months ended September 30 , 2021 and includes Firdapse for the nine months ended September 30 , 2020 , each calculated in accordance with Generally Accepted Accounting Principles in the United States ( U.S. GAAP ) . Sanofi Genzyme ( Genzyme ) is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties . Refer to page 10 for a table showing Net Product Revenues by product . In January 2020 , BioMarin divested the Firdapse assets to a third party in a sale transaction . The sale is reflected in the Company's consolidated financial statements for the nine months ended September 30 , 2020 ; as a result of the transaction BioMarin no longer recognizes Net Product Revenues from Firdapse . 1